Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase NA 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 16Terminated 6Recruiting 5Active not recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Conditions

Breast Neoplasms 412Carcinoma, Non-Small-Cell Lung 285Prostatic Neoplasms 208Neoplasms 202Neoplasm Metastasis 179Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 157Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 104Carcinoma, Renal Cell 104Brain Neoplasms 89Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 84Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 59

Interventions

rhoA GTP-Binding Protein 1eculizumab 1CK-2017357 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Myasthenia Gravis × Clear all
NCT04226170 2025-09-11

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

DAS-MG, Inc

Phase 2 Terminated
2 enrolled

Myasthenia Gravis

NCT05218096 2025-01-09

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 2 Terminated
70 enrolled 14 charts

Myasthenia Gravis

NCT03896295 2023-06-27

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

Momenta Pharmaceuticals, Inc.

Phase 2 Terminated
37 enrolled 40 charts

Myasthenia Gravis

NCT02102594 2019-12-03

TAVAB

Charite University, Berlin, Germany

Phase 2 Terminated
11 enrolled

Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Myasthenia Gravis

NCT00727194 2019-09-24

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 2 Terminated
14 enrolled 23 charts

Myasthenia Gravis

NCT01268280 2019-09-24

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Cytokinetics

Phase 2 Terminated
32 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡